T. Rowe Price Associates
COGT icon

T. Rowe Price Associates’s Cogent Biosciences COGT Stock Holding History

T. Rowe Price Associates’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$180M Buy
4,652,727
+1,439,912
+45% +$50.4M 0.02% 531
2026
Q1 		$124M Buy
3,212,815
+648,753
+25% +$24M 0.01% 574
2025
Q4 		$91.1M Buy
2,564,062
+2,474,346
+2,758% +$69.6M 0.01% 647
2025
Q3 		$1.29M Buy
89,716
+16,564
+23% +$196K ﹤0.01% 1946
2025
Q2 		$526K Buy
73,152
+18,766
+35% +$104K ﹤0.01% 2275
2025
Q1 		$326K Buy
54,386
+4,743
+10% +$37.2K ﹤0.01% 2427
2024
Q4 		$388K Buy
49,643
+5,486
+12% +$54.7K ﹤0.01% 2392
2024
Q3 		$477K Buy
44,157
+3,540
+9% +$34.5K ﹤0.01% 2265
2024
Q2 		$343K Buy
40,617
+5,406
+15% +$41K ﹤0.01% 2358
2024
Q1 		$237K Buy
35,211
+4,030
+13% +$24.9K ﹤0.01% 2538
2023
Q4 		$184K Buy
31,181
+1,526
+5% +$11.7K ﹤0.01% 2570
2023
Q3 		$290K Buy
29,655
+4,286
+17% +$50.8K ﹤0.01% 2346
2023
Q2 		$301K Buy
25,369
+1,868
+8% +$21.4K ﹤0.01% 2365
2023
Q1 		$254K Buy
23,501
+12,379
+111% +$158K ﹤0.01% 2426
2022
Q4 		$129K Buy
11,122
+1,018
+10% +$12.6K ﹤0.01% 2660
2022
Q3 		$151K Buy
+10,104
New +$138K ﹤0.01% 2627

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates's COGT Position: Q2 2026 in Review

T. Rowe Price Associates increased its Cogent Biosciences (COGT) stake by 45% in Q2 2026, buying an estimated $50.4M and bringing the position to 4,652,727 shares worth $180M. The position accounts for 0.02% of the portfolio, ranked #531.

T. Rowe Price Associates first reported a position in COGT in Q3 2022 and has held it in 16 quarters since. 323 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • T. Rowe Price Associates held 4,652,727 shares of Cogent Biosciences worth $180M as of Q2 2026.
  • T. Rowe Price Associates bought 1,439,912 Cogent Biosciences shares in Q2 2026, an estimated $50.4M.
  • Cogent Biosciences made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #531 holding.
  • T. Rowe Price Associates first reported a position in Cogent Biosciences in Q3 2022 and has held it in 16 quarters since.
  • 323 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.